Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700407 | 1.00 | LMNA (0.41) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5700353 | 0.97 | LMNA (0.40) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| SCHEMBL5700582 | 0.91 | SMN1; SMN2 (0.42) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| SCHEMBL5700585 | 0.91 | SMN1; SMN2 (0.42) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5700596 | 0.89 | SMN1; SMN2 (0.40) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| SCHEMBL5700600 | 0.86 | SMN1; SMN2 (0.39) | LMNASCN5ASCN2ACYP1A2CYP3A4 | |
| SCHEMBL3068165 | 0.74 | NAAA (0.49) | LMNASMN1; SMN2TSHRNAAAALDH1A1 | |
| SCHEMBL3068162 | 0.74 | NAAA (0.49) | LMNASMN1; SMN2TSHRNAAAALDH1A1 | |
| SCHEMBL975934 | 0.72 | NAAA (0.42) | SCN5ASCN2ANAAACES2CES1 | |
| SCHEMBL9645767 | 0.70 | NAAA (0.55) | SMN1; SMN2TSHRNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141687-B2 | N'-substituted N-acylamidine metal transition complexes and their use as catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1569947-B1 | N'-SUBSTITUTED N-ACYLAMIDINE METAL TRANSITION COMPLEXES AND THEIR USE AS CATALYSTS | BASF AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-20060069275-A1 | N'-substituded n-acylamidine metal transition complexes and their use as catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | US | disclosed |
| EP-1569947-A1 | N'-SUBSTITUTED N-ACYLAMIDINE METAL TRANSITION COMPLEXES AND THEIR USE AS CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050670-A1 | N'-SUBSTITUTED N-ACYLAMIDINE METAL TRANSITION COMPLEXES AND THEIR USE AS CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069275-A1 | N'-substituded n-acylamidine metal transition complexes and their use as catalysts | NR1I3, NR0B1, NR4A1 | LMNA 3888/4885SCN5A 1024/4885SCN2A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.